loading...| Preferred Name |
Dersimelagon |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166490 |
| CAS_Registry |
1835256-48-8 |
| code |
C166490 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
An orally bioavailable selective, non-peptide melanocortin-1 receptor (MC1R; melanocyte-stimulating hormone receptor; MSHR; melanin-activating peptide receptor; melanotropin receptor) agonist, that can potentially be used to prevent phototoxicity. Upon administration, dersimelagon targets, binds to and activates MC1R. This may prevent phototoxicity and related pain in erythropoietic protoporphyria (EPP) or X-Linked Protoporphyria (XLP) patients. MC1R, a G protein-coupled receptor that binds to melanocortins and are located on melanocytes, is involved in regulating mammalian skin and hair color. |
| Display_Name |
Dersimelagon |
| FDA_UNII_Code |
1CWH5SV4G2 |
| FULL_SYN |
Dersimelagon MC1R Agonist MT-7117 MT 7117 DERSIMELAGON MT-7117 1-[2-[(3R,4S)-1-[(3S,4S)-1-Cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl]piperidine-4-carboxylic Acid MT7117 |
| Has_Target | |
| label |
Dersimelagon |
| NCI_Drug_Dictionary_ID |
802028 |
| NCI_META_CUI |
CL971489 |
| PDQ_Closed_Trial_Search_ID |
802028 |
| PDQ_Open_Trial_Search_ID |
802028 |
| Preferred_Name |
Dersimelagon |
| prefixIRI |
Thesaurus:C166490 |
| prefLabel |
Dersimelagon |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||